298 related articles for article (PubMed ID: 33987655)
21. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
[TBL] [Abstract][Full Text] [Related]
22. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
Jagannathan S
Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
[TBL] [Abstract][Full Text] [Related]
23. Direct interplay between two candidate genes in FSHD muscular dystrophy.
Ferri G; Huichalaf CH; Caccia R; Gabellini D
Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
[TBL] [Abstract][Full Text] [Related]
24. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.
Mitsuhashi H; Mitsuhashi S; Lynn-Jones T; Kawahara G; Kunkel LM
Hum Mol Genet; 2013 Feb; 22(3):568-77. PubMed ID: 23108159
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit
Lu-Nguyen N; Dickson G; Malerba A; Popplewell L
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884928
[TBL] [Abstract][Full Text] [Related]
26. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
Nunes AM; Ramirez MM; Garcia-Collazo E; Jones TI; Jones PL
Hum Mol Genet; 2024 May; 33(10):872-883. PubMed ID: 38340007
[TBL] [Abstract][Full Text] [Related]
27. DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis.
Young JM; Whiddon JL; Yao Z; Kasinathan B; Snider L; Geng LN; Balog J; Tawil R; van der Maarel SM; Tapscott SJ
PLoS Genet; 2013 Nov; 9(11):e1003947. PubMed ID: 24278031
[TBL] [Abstract][Full Text] [Related]
28. MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy.
Runfola V; Giambruno R; Caronni C; Pannese M; Andolfo A; Gabellini D
Cell Rep; 2023 Sep; 42(9):113120. PubMed ID: 37703175
[TBL] [Abstract][Full Text] [Related]
29. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
[TBL] [Abstract][Full Text] [Related]
30. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
31. Deciphering transcription dysregulation in FSH muscular dystrophy.
Ehrlich M; Lacey M
J Hum Genet; 2012 Aug; 57(8):477-84. PubMed ID: 22718021
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.
Bosnakovski D; Shams AS; Yuan C; da Silva MT; Ener ET; Baumann CW; Lindsay AJ; Verma M; Asakura A; Lowe DA; Kyba M
J Clin Invest; 2020 May; 130(5):2465-2477. PubMed ID: 32250341
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
34. The DUX4-HIF1α Axis in Murine and Human Muscle Cells: A Link More Complex Than Expected.
Nguyen TH; Limpens M; Bouhmidi S; Paprzycki L; Legrand A; Declèves AE; Heher P; Belayew A; Banerji CRS; Zammit PS; Tassin A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542301
[TBL] [Abstract][Full Text] [Related]
35. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
Wallace LM; Liu J; Domire JS; Garwick-Coppens SE; Guckes SM; Mendell JR; Flanigan KM; Harper SQ
Mol Ther; 2012 Jul; 20(7):1417-23. PubMed ID: 22508491
[TBL] [Abstract][Full Text] [Related]
36. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
Yao Z; Snider L; Balog J; Lemmers RJ; Van Der Maarel SM; Tawil R; Tapscott SJ
Hum Mol Genet; 2014 Oct; 23(20):5342-52. PubMed ID: 24861551
[TBL] [Abstract][Full Text] [Related]
37. Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy.
Bouwman LF; den Hamer B; van den Heuvel A; Franken M; Jackson M; Dwyer CA; Tapscott SJ; Rigo F; van der Maarel SM; de Greef JC
Mol Ther Nucleic Acids; 2021 Dec; 26():813-827. PubMed ID: 34729250
[TBL] [Abstract][Full Text] [Related]
38. Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies.
Greco A; Straasheijm KR; Mul K; van den Heuvel A; van der Maarel SM; Joosten LAB; van Engelen BGM; Pruijn GJM
J Neuromuscul Dis; 2021; 8(5):801-814. PubMed ID: 34024774
[TBL] [Abstract][Full Text] [Related]
39. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
40. Asymmetric bidirectional transcription from the FSHD-causing D4Z4 array modulates DUX4 production.
Block GJ; Petek LM; Narayanan D; Amell AM; Moore JM; Rabaia NA; Tyler A; van der Maarel SM; Tawil R; Filippova GN; Miller DG
PLoS One; 2012; 7(4):e35532. PubMed ID: 22536400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]